Jiangsu Aidea Pharmaceutical 관리

관리 기준 확인 1/4

Jiangsu Aidea Pharmaceutical CEO는 Jie Zhang, Aug2023 에 임명되었습니다 의 임기는 1.25 년입니다. 는 CN¥ 859.91K 가치에 해당하는 회사 주식의 0.022% 직접 소유합니다. 859.91K. 경영진과 이사회의 평균 재임 기간은 각각 1.7 년과 4.2 년입니다.

주요 정보

Jie Zhang

최고 경영자

CN¥3.0m

총 보상

CEO 급여 비율	n/a
CEO 임기	1.3yrs
CEO 소유권	0.02%
경영진 평균 재임 기간	1.7yrs
이사회 평균 재임 기간	4.2yrs

최근 관리 업데이트

Recent updates

Unpleasant Surprises Could Be In Store For Jiangsu Aidea Pharmaceutical Co., Ltd.'s (SHSE:688488) Shares

Oct 16

Jiangsu Aidea Pharmaceutical Co., Ltd.'s (SHSE:688488) 30% Share Price Plunge Could Signal Some Risk

Jun 29

Jiangsu Aidea Pharmaceutical (SHSE:688488) Is Making Moderate Use Of Debt

Jun 07

Jiangsu Aidea Pharmaceutical Co., Ltd.'s (SHSE:688488) Shares Climb 27% But Its Business Is Yet to Catch Up

Mar 01

CEO

Jie Zhang (54 yo)

1.3yrs

테뉴어

CN¥3,013,500

보상

Mr. Jie Zhang is CEO & President of Jiangsu Aidea Pharmaceutical Co. Ltd. from August 2023 and has been its Director since March 14, 2023. Mr. Zhang was Executive Vice President of Jiangsu Aidea Pharmaceut...

리더십 팀

이름	위치	테뉴어	보상	소유권
Jie Zhang	CEO, President & Director	1.3yrs	CN¥3.01m	0.022% CN¥ 859.9k
Jun Wang	VP & Director	5.8yrs	CN¥872.80k	0.49% CN¥ 19.0m
Qi Hong	Senior Vice President	2.8yrs	CN¥1.11m	데이터 없음
Ke Yu	VP & Director	4.2yrs	CN¥929.00k	0.0037% CN¥ 141.1k
Guang Rong Wang	VP & Director	1.7yrs	CN¥876.30k	0.016% CN¥ 625.9k
Hong Qin	Vice President	1.6yrs	CN¥2.46m	데이터 없음
Yan Liu	Secretary of the Board	1.6yrs	CN¥679.70k	데이터 없음

1.7yrs

평균 재임 기간

47yo

평균 연령

경험이 풍부한 관리: 688488 의 관리팀은 경험 (평균 재직 기간 1.7 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jie Zhang	CEO, President & Director	1.7yrs	CN¥3.01m	0.022% CN¥ 859.9k
Jun Wang	VP & Director	5.8yrs	CN¥872.80k	0.49% CN¥ 19.0m
Ke Yu	VP & Director	4.2yrs	CN¥929.00k	0.0037% CN¥ 141.1k
Guang Rong Wang	VP & Director	5.8yrs	CN¥876.30k	0.016% CN¥ 625.9k
Heliang Fu	Chairman	10.8yrs	CN¥1.12m	0.65% CN¥ 25.2m
Zijian Guo	Independent Director	1.2yrs	CN¥29.40k	데이터 없음
Heng Yu	Chairman of the Supervisory Board	4.2yrs	데이터 없음	1.2% CN¥ 46.4m
Feng Ying He	Supervisor	4.2yrs	데이터 없음	데이터 없음
Guang Ji Wang	Independent Director	5.5yrs	CN¥100.00k	데이터 없음
Xiao Yan Qi	Independent Director	2.7yrs	CN¥100.00k	데이터 없음

4.2yrs

평균 재임 기간

51.5yo

평균 연령

경험이 풍부한 이사회: 688488 의 이사회는 경험(평균 재직 기간 4.2 년)으로 간주됩니다.

Jiangsu Aidea Pharmaceutical 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Less than half of directors are independent

Jiangsu Aidea Pharmaceutical Co., Ltd., Annual General Meeting, May 13, 2024

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: CN¥0.032 loss per share (vs CN¥0.089 loss in 3Q 2023)

Unpleasant Surprises Could Be In Store For Jiangsu Aidea Pharmaceutical Co., Ltd.'s (SHSE:688488) Shares

Jiangsu Aidea Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

New major risk - Share price stability

Second quarter 2024 earnings released: CN¥0.085 loss per share (vs CN¥0.018 loss in 2Q 2023)

Less than half of directors are independent

Jiangsu Aidea Pharmaceutical Co., Ltd.'s (SHSE:688488) 30% Share Price Plunge Could Signal Some Risk

Jiangsu Aidea Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Jiangsu Aidea Pharmaceutical (SHSE:688488) Is Making Moderate Use Of Debt

Full year 2023 earnings released: CN¥0.18 loss per share (vs CN¥0.30 loss in FY 2022)

Jiangsu Aidea Pharmaceutical Co., Ltd., Annual General Meeting, May 13, 2024

Jiangsu Aidea Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Jiangsu Aidea Pharmaceutical Co., Ltd.'s (SHSE:688488) Shares Climb 27% But Its Business Is Yet to Catch Up

Full year 2023 earnings released: CN¥0.19 loss per share (vs CN¥0.30 loss in FY 2022)

Second quarter 2023 earnings released: CN¥0.018 loss per share (vs CN¥0.11 loss in 2Q 2022)

New major risk - Share price stability

Jiangsu Aidea Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 22, 2023

Full year 2022 earnings released: CN¥0.29 loss per share (vs CN¥0.07 loss in FY 2021)

Full year 2022 earnings released: CN¥0.29 loss per share (vs CN¥0.07 loss in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: CN¥0.02 loss per share (vs CN¥0.045 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.11 loss per share (vs CN¥0.003 profit in 2Q 2021)

Jiangsu Aidea Pharmaceutical Co., Ltd. (SHSE:688488) agreed to acquire 19.9646% stake in Nanjing Nanda Pharmaceutical Co., Ltd. from Jiangsu Sheng Feng Medical Technology Company Limited for CNY 86 million.

First quarter 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.03 profit in 1Q 2021)

Full year 2021 earnings released: CN¥0.07 loss per share (vs CN¥0.10 profit in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings released: CN¥0.045 loss per share (vs CN¥0.014 profit in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.003 (vs CN¥0.053 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.03 (vs CN¥0.01 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.10 (vs CN¥0.09 in FY 2019)

New 90-day low: CN¥19.66

New 90-day low: CN¥19.86

New 90-day low: CN¥26.00

New 90-day low: CN¥26.80

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령